{"nctId":"NCT00082433","briefTitle":"Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer","startDateStruct":{"date":"2003-11"},"conditions":["Cancer","Breast Cancer"],"count":1221,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: Ixabepilone + Capecitabine"]},{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Capecitabine"]}],"interventions":[{"name":"Ixabepilone + Capecitabine","otherNames":["IXEMPRAÂ®","Epothilone"]},{"name":"Capecitabine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"* Patients must have received prior treatment which included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).\n* Patients must have received no more than two prior chemotherapy regimens. Patients who have not received treatment for metastatic disease must have relapsed within one year.\n* Patients may not have any history of brain and/or leptomeningeal metastases.\n* Patients may not have Grade 2 or worse neuropathy at the time of study entry.\n* Patients may not have had prior treatment with any epothilones and/or capecitabine (i.e. Xeloda)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"PFS was defined for each patient as the time in months from randomization to the date of progression. Patients who died without a reported prior progression were considered to have progressed on their date of death. Patients who did not progress or die were censored on the date of their last tumor assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.24","spread":null},{"groupId":"OG001","value":"4.40","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate (RR)","description":"RR=number of patients in that group whose best response is \"partial\"(30% decrease in the sum of the longest diameter of target lesions) or \"complete\" (disappearance of all target lesions), according to the 4-item Response Evaluation Criteria in Solid Tumors (RECIST), divided by the total number of response-evaluable participants","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.3","spread":null},{"groupId":"OG001","value":"28.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Measured from the time RECIST criteria (described in previous outcome measure) were first met for \"complete\" or \"partial\" response until first date of documented disease progression or death. Patients who neither relapsed nor died were censored on the date of last tumor assessment. Median w/ 95% CI estimated using Kaplan Meier Product Limit Method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Response","description":"Time to response was defined as the time from the first dose of study therapy until measurement criteria were first met for \"partial\" or \"complete\" (whichever status was recorded first) per RECIST criteria (a 4-item scale described in the previous outcome measure).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment-Related Safety Summary","description":"Laboratory values, adverse events, and other symptoms were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTC) Version 3.0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"458","spread":null},{"groupId":"OG001","value":"240","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"286","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)","description":"Quality of life, as measured by the FBSI, an 8-item, participant-reported instrument to measure symptoms. Each item has 5 possible responses ranging from 0 (not at all) to 4 (very much). The scoring was conducted according to the Functional Assessment of Chronic Illness Therapy manual, Version 4; higher scores reflect fewer symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"13.7"},{"groupId":"OG001","value":"0.0","spread":"4.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"15.4"},{"groupId":"OG001","value":"0.5","spread":"5.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"17.4"},{"groupId":"OG001","value":"0.7","spread":"5.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"17.3"},{"groupId":"OG001","value":"1.1","spread":"5.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"17.0"},{"groupId":"OG001","value":"1.5","spread":"5.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"15.7"},{"groupId":"OG001","value":"1.2","spread":"5.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"16.8"},{"groupId":"OG001","value":"1.7","spread":"5.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"17.3"},{"groupId":"OG001","value":"1.1","spread":"5.4"}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Overall survival was defined as the time in months from randomization until the date of death. For those patients who had not died, survival duration was censored at the last date the patient was known to be alive. Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.39","spread":null},{"groupId":"OG001","value":"15.64","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":192,"n":603},"commonTop":["PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME","NAUSEA","DIARRHOEA","FATIGUE","VOMITING"]}}}